Brokerages Set Guardian Pharmacy Services, Inc. (NYSE:GRDN) Price Target at $43.83

Guardian Pharmacy Services, Inc. (NYSE:GRDN) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $43.8333.

A number of equities analysts recently commented on the company. Truist Financial raised their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Wall Street Zen raised Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a report on Sunday, August 9th. Bank of America boosted their price target on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Oppenheimer lifted their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Finally, Weiss Ratings raised Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, August 20th.

Guardian Pharmacy Services Stock Performance

Guardian Pharmacy Services stock opened at $39.24 on Thursday. The company’s 50 day simple moving average is $39.80 and its 200-day simple moving average is $38.01. Guardian Pharmacy Services has a 1 year low of $23.14 and a 1 year high of $47.02. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 38.09, a price-to-earnings-growth ratio of 2.01 and a beta of 0.06.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The firm had revenue of $351.77 million during the quarter, compared to analysts’ expectations of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. Equities analysts expect that Guardian Pharmacy Services will post 1.19 earnings per share for the current year.

Hedge Funds Weigh In On Guardian Pharmacy Services

Several institutional investors and hedge funds have recently added to or reduced their stakes in GRDN. Dynamic Technology Lab Private Ltd purchased a new position in shares of Guardian Pharmacy Services during the 1st quarter worth approximately $233,000. JPMorgan Chase & Co. boosted its stake in shares of Guardian Pharmacy Services by 48.0% in the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock valued at $128,000 after buying an additional 1,956 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Guardian Pharmacy Services by 1,783.1% in the second quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock valued at $317,000 after buying an additional 14,104 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Guardian Pharmacy Services by 121.1% in the second quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock valued at $345,000 after buying an additional 8,860 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Guardian Pharmacy Services during the second quarter worth $214,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.